Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Summary: Background: The role of gut microbiota in the pathophysiology of irritable bowel syndrome (IBS) is supported by various lines of evidence, including differences in mucosal and faecal microbiota between patients with IBS and healthy individuals, development of post‐infectious IBS, and the efficacy of some probiotics and nonsystemic antibiotics (e.g. rifaximin). Aim: To review the literature regarding the role of rifaximin in IBS and its potential mecha‐nism(s) of action. Methods: A literature search was conducted using the terms ‘rifaximin’, ‘irritable bowel syndrome’ and ‘mechanism of action’. Results: Rifaximin was approved in 2015 for the treatment of IBS with diarrhoea. In contrast to other currently available IBS therapies that require daily administration to maintain efficacy, 2‐week rifaximin treatment achieved symptom improvement that persisted ≥12 weeks post‐treatment. The mechanisms of action of rifaximin, therefore, may extend beyond direct bactericidal effects. Data suggest that rifaximin may decrease host proinflammatory responses to bacterial products in patients with IBS. In some cases, small intestinal bacterial overgrowth (SIBO) may play a role in the clinical symptoms of IBS. Because of the high level of solubility of rifaximin in the small intestine, rifaximin may reset microbial diversity in this environment. Consistent with this hypothesis, rifaximin has antibiotic efficacy against isolates derived from patients with SIBO. Conclusion: Resetting microbial diversity via rifaximin use may lead to a decrease in bacterial fermentation and a reduction in the clinical symptoms of IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rajilić–Stojanović, M., Biagi, E., Heilig, H. G. H. J., Kajander, K., Kekkonen, R. A., Tims, S., & de Vos, W. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.043 · Cited by 1,041
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 3×
“001), and both of these improvements were maintained for at least 12 weeks post-treatment.(13)A third randomised,”
BackgroundMethodInfluentialSelf-citationKassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780 · cited 2×
“The study showed that rifaximin was potent against isolates of SIBO and provides a rationale (at least in part) for the efficacy of rifaximin in ameliorating symptoms of IBS.22 Indeed, other studies have reported reductions in hydrogen production along with concomitant improvements in symptoms of IBS with rifaximin.12…”
MethodSelf-citationMalinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699
Dinan, T. G., Quigley, E. M. M., Ahmed, S. M. M., Scully, P., O’Brien, S., O’Mahony, L., O’Mahony, S., Shanahan, F., & Keeling, P. W. N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.033 · Cited by 636
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430 · cited 6×
“ment was associated with a significant reduction in Veillonellaceae quantity and increase in Eubacteriaceae; rifaximin had previously been shown to reduce the virulence of Enterobacteriaceae.(56) In a study of cytokine pro-”
BackgroundInfluentialCarroll, I. M., Ringel‐Kulka, T., Siddle, J. P., & Ringel, Y. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01891.x · Cited by 425
Ford, A. C., Spiegel, B. M. R., Talley, N. J., & Moayyedi, P. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.031 · Cited by 351
Cited by
Antibiotics and the nervous system: More than just the microbes?
Champagne-Jorgensen, K., Kunze, W. A., Forsythe, P., Bienenstock, J., & McVey Neufeld, K.-A. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.12.014 · Cited by 92
Acosta, A., Camilleri, M., Shin, A., Nord, S. L., O'Neill, J., Gray, A. V., Lueke, A. J., Donato, L. J., Burton, D. D., Szarka, L. A., et al. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.32 · Cited by 88
Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome
Saito, Y. A., Almazar, A. E., Tilkes, K. E., Choung, R. S., Van Norstrand, M. D., Schleck, C. D., Zinsmeister, A. R., & Talley, N. J. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15077 · Cited by 79
“This study also did not utilise the FDA outcomes for IBS.”
BackgroundInfluentialNon-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders
Barbaro, M. R., Cremon, C., Wrona, D., Fuschi, D., Marasco, G., Stanghellini, V., & Barbara, G. (2020) · Nutrients · doi:10.3390/nu12123735 · Cited by 66
Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia?
Tziatzios, G., Giamarellos-Bourboulis, E. J., Papanikolaou, I. S., Pimentel, M., Dimitriadis, G. D., & Triantafyllou, K. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.07.005 · Cited by 30
Self-citationThe Intestinal Microbiota in the Irritable Bowel Syndrome
Collins, S. M. (2016) · International Review of Neurobiology · doi:10.1016/bs.irn.2016.08.003 · Cited by 30
Metadata
- Authors
- Pimentel, M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2015-11-30
- Volume
- 43
- Issue
- S1
- Pages
- 37-49
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2176306270
- Cited by
- 75
- References
- 22
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.